Affiliation:
1. From the Allergy and Clinical Immunology Division, Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada; and
Abstract
Oral immunotherapy (OIT) protocols are not standardized, and a wide heterogeneity exists in the literature. OIT protocol variables include the initiation approach (fixed dose versus oral food challenge), buildup speed (slow versus fast), target maintenance dose (low versus high target dose), type of food used, and use of adjuvants among other variables. Most protocols start with an initial escalation day, which is a series of extremely low doses to safely identify the patients who are most allergic, followed by a buildup period over several months to years until the final target maintenance dose is achieved. Doses are generally increased every 1‐2 weeks by a factor of 1.25 to 2 and are adapted based on the patient’s symptoms. Protocols are increasingly favoring low-maintenance doses over traditional high maintenance doses, although this needs to be discussed and adapted based on the patient’s preferences. Accelerated OIT schedules with using a short treatment of omalizumab can be considered in severe food allergy cases.
Publisher
Oceanside Publications Inc.
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference72 articles.
1. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy;Begin;Allergy Asthma Clin Immunol,2020
2. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective;Vickery;J Allergy Clin Immunol,2017
3. Conducting an oral food challenge: an update to the 2009 Adverse Reactions to Foods Committee Work Group report;Bird;J Allergy Clin Immunol Pract,2020
4. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report;Sampson;J Allergy Clin Immunol,2012
5. Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy;Blumchen;J Allergy Clin Immunol Pract,2019
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献